Asta Baranauskaite
Overview
Explore the profile of Asta Baranauskaite including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
800
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maharaj N, Uppada D, Reddy N, Reddy P, Batalov A, Lvanova D, et al.
Arthritis Res Ther
. 2024 Dec;
26(1):225.
PMID: 39709462
Objectives: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from rituximab [US-licensed rituximab: Reference Product (RP); EU-approved rituximab: Reference Medicinal Product (RMP)] to DRL_RI (proposed...
2.
Snipaitiene A, Slegeryte A, Uktveris R, Sileikiene R, Jakucionis P, Baranauskaite A, et al.
Front Pediatr
. 2024 Sep;
12:1414384.
PMID: 39328590
Introduction: Juvenile idiopathic arthritis (JIA) is a group of rare musculoskeletal disorders with chronic inflammation of joints, typically manifesting before the age of 16 years. The assessment of disease activity...
3.
Poddubnyy D, Pournara E, Zielinska A, Baranauskaite A, Munoz Jimenez A, Sadhu S, et al.
Ther Adv Musculoskelet Dis
. 2021 Oct;
13:1759720X211051471.
PMID: 34707696
Background: This study aimed to evaluate the efficacy and safety of secukinumab 150 mg compared with placebo in the management of spinal pain and disease activity in patients with axial...
4.
Blazeviciene A, Vanckaviciene A, Paukstaitiene R, Baranauskaite A
Healthcare (Basel)
. 2021 Aug;
9(8).
PMID: 34442100
Attitudes towards interprofessional education are key factors that shape students' behaviour during interprofessional practice. An interprofessional approach to training and practice is "unique", important, and challenging. Interprofessional education allows for...
5.
Pavelka K, Szekanecz Z, Damjanov N, Anic B, Tomsic M, Mazurov V, et al.
Drugs Context
. 2020 Oct;
9.
PMID: 33123205
Background: In the randomized, phase III, global SELECT-COMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate...
6.
Stropuviene S, Baranauskaite A, Bukauskiene L, Zaikauskiene J
Acta Med Litu
. 2018 Sep;
25(2):112-123.
PMID: 30210246
Background: To provide data on the use of anti-cyclic citrullinated peptide antibody (anti-CCP) and other routinely used clinical parameters and to assess the impact of anti-CCP status on therapeutic decisions,...
7.
Weinblatt M, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, et al.
Arthritis Rheumatol
. 2018 Feb;
70(6):832-840.
PMID: 29439289
Objective: The 24-week equivalent efficacy and comparable safety results of the biosimilar SB5 and reference adalimumab (ADA) from the phase III randomized study in patients with moderate-to-severe rheumatoid arthritis (RA)...
8.
Smolen J, Choe J, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, et al.
Ann Rheum Dis
. 2017 Oct;
77(2):234-240.
PMID: 29042358
Objectives: Efficacy, safety and immunogenicity results from the phase III study of SB2, a biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This transition period compared results...
9.
Emery P, Vencovsky J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, et al.
Rheumatology (Oxford)
. 2017 Oct;
56(12):2093-2101.
PMID: 28968793
Objective: To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA. Methods: In a phase 3, randomized, double-blind, multicentre...
10.
Smolen J, Choe J, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, et al.
Rheumatology (Oxford)
. 2017 Sep;
56(10):1771-1779.
PMID: 28957563
Objectives: SB2 is a biosimilar to the reference infliximab (INF). Similar efficacy, safety and immunogenicity between SB2 and INF up to 30 weeks were previously reported. This report investigates such...